Nutex Health (NASDAQ:NUTX) Issues Quarterly Earnings Results, Beats Expectations By $0.17 EPS

Posted by Brenda Bartman on Nov 6th, 2026

Nutex Health (NASDAQ:NUTX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $5.71 EPS for the quarter, beating the consensus estimate of $5.54 by $0.17, FiscalAI reports. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. The business had revenue of $217.61 million for the quarter, compared to analysts’ expectations of $214.82 million.

Nutex Health Stock Down 5.6%

NUTX stock traded down $11.58 during midday trading on Thursday, hitting $193.64. The company’s stock had a trading volume of 148,231 shares, compared to its average volume of 138,168. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.00 and a quick ratio of 4.96. Nutex Health has a twelve month low of $83.99 and a twelve month high of $226.16. The company’s fifty day moving average price is $203.37 and its 200 day moving average price is $151.24. The stock has a market capitalization of $1.33 billion, a P/E ratio of 8.06 and a beta of 0.66.

Analyst Ratings Changes

NUTX has been the topic of a number of research reports. Wall Street Zen lowered Nutex Health from a “buy” rating to a “hold” rating in a report on Saturday, October 31st. Weiss Ratings upgraded Nutex Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, October 6th. Lake Street Capital reissued a “buy” rating and issued a $310.00 target price (up from $235.00) on shares of Nutex Health in a research report on Tuesday, August 11th. B. Riley Financial restated a “buy” rating on shares of Nutex Health in a research note on Friday, September 4th. Finally, LADENBURG THALM/SH SH started coverage on Nutex Health in a research report on Monday, October 26th. They set a “buy” rating and a $336.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Nutex Health currently has a consensus rating of “Moderate Buy” and an average price target of $323.67.

Get Our Latest Stock Analysis on Nutex Health

Insider Buying and Selling

In other news, Director Scott Saunders sold 203 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $214.25, for a total transaction of $43,492.75. Following the completion of the transaction, the director directly owned 400 shares in the company, valued at $85,700. This represents a 33.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 44.68% of the stock is owned by company insiders.

About Nutex Health

(Get Free Report)

Nutex Health, Inc (NASDAQ:NUTX) is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.